FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma By Ogkologos - January 10, 2025 863 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Potential Clinical Utility of ctDNA-based Surveillance in Patients Treated with ICI August 12, 2020 Study Links Mental Health Treatment to Improved Cancer Survival July 10, 2020 ESMO Welcomes New Cancer Focused UN Political Declaration on Non-Communicable Diseases October 6, 2025 Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer August 29, 2018 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria Professor Ian Tomlinson: “Philanthropy is priceless to science” Can Age Affect Response to Immune Checkpoint Inhibitors? A Remarkable Group of Patients with Haematological Disorders with No or...
